Key result
Transitioning from intravenous glyceryl trinitrate to oral isosorbide dinitrate in patients with acute coronary syndromes reduced the augmentation index from 8% to 5% (P=0.05) without rebound ischemia.
Why the study?
Does transition from intravenous glyceryl trinitrate to oral isosorbide dinitrate prevent rebound vasoconstriction and ischaemia in patients with acute coronary syndromes?
Observational (n=26)
Does transition from intravenous glyceryl trinitrate to oral isosorbide dinitrate prevent rebound vasoconstriction and ischaemia in patients with acute coronary syndromes?
Absolute Event Rate: 5% vs 8%
p-value: p=0.05
Transitioning from intravenous glyceryl trinitrate to low-dose oral isosorbide dinitrate in patients with acute coronary syndromes provides incremental vasodilatation without rebound ischemia.
May support transition from intravenous glyceryl trinitrate to oral isosorbide dinitrate without rebound in acute coronary syndromes; hypothesis-generating pending randomized trials.
Glyceryl trinitrate (GTN) is frequently infused intravenously as a component of the management of acute coronary syndromes (ACS). Abrupt cessation of GTN infusion after periods of more than 24 h administration often induces rebound vasoconstriction reflecting 'pseudotolerance'; this is also the basis of the 'zero hour phenomenon' during chronic nitrate therapy. The efficacy of oral nitrate regimens to prevent vasoconstriction following cessation of intravenous GTN has not been previously examined. Therefore, we investigated the effects of transition from intravenous GTN to oral isosorbide dinitrate (ISDN) on a parameter of apparent arterial stiffness in patients with ACS. 2. The effects of GTN infusion at 5 microg/min on augmentation index (AIx) were quantified in patients (n = 10) with stable angina pectoris in order to establish the magnitude of effect on apparent arterial stiffness. 3. This infusion rate of GTN reduced AIx from 23 +/- 10% (SD) to 3 +/- 14% (SD) (P < 0.01). The effect of transition from GTN infusion of greater than 24 h duration to ISDN (10 mg tds) were examined in patients (n = 16) with ACS (unstable angina/non-Q-wave myocardial infarction). No patient developed recurrent angina during the 24 h following cessation of GTN infusion. The level of AIx was 8 +/- 4% (SD) prior to GTN cessation and fell to 5 +/- 6% (SD) on ISDN (P = 0.05). 4. Thus, in patients treated for ACS, transition from intravenous GTN to low dose oral ISDN is associated with an incremental vasodilatation and no evidence of 'rebound' ischaemia.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2005) conducted an observational in Acute coronary syndromes and stable angina pectoris (n=26). Transition from intravenous glyceryl trinitrate (GTN) to oral isosorbide dinitrate (ISDN) vs. Baseline (prior to GTN cessation) was evaluated on Augmentation index (AIx) (p=0.05). Transitioning from intravenous glyceryl trinitrate to oral isosorbide dinitrate in patients with acute coronary syndromes reduced the augmentation index from 8% to 5% (P=0.05) without rebound ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: